Niaid VRC pre-clinical assessment
Active Awarded Last action
- Contract number
- 75N91024F00021
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $16,097,583
Award facts
- Contract value 74% obligated
-
- $16,097,583.00 Current, with exercised options
- $21,882,796.00 Potential, with all options
- Completion date 33% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Award Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $1,488,074 | |
| Exercise an Option | $2,487,934 | |
| Exercise an Option | $3,765,850 | |
| Original award | $8,355,725 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on June 17, 2024, under the NIAID master indefinite delivery contract HHSN261201500003I for preclinical assessment activities supporting vaccine and therapeutic development, with a ceiling value of $21.88 million and an ultimate completion date of August 31, 2031.
Place of performance is Frederick, MD. The order carries cost-plus-award-fee pricing. Service Contract Inventory reporting shows government-invoiced activity of $5,000 in FY2024 (0.3 FTEs, 605 contractor hours at $8.92/hr) and $2 million in FY2025 (2.6 FTEs, 5,303 contractor hours at $383.93/hr), reflecting a substantial year-over-year increase in labor engagement and blended hourly rate. In FY2025, 95% of contractor hours were subcontracted out across five subcontractors, indicating significant teaming depth on this order's recent execution.
Quick answers
Who was awarded contract 75N91024F00021?
75N91024F00021 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on June 17, 2024.
How much is contract 75N91024F00021 worth?
The government has obligated $16,097,583 on 75N91024F00021. Its potential value, with all options, is $21,882,796.
Which agency awarded contract 75N91024F00021?
National Cancer Institute (National Institutes of Health) awarded 75N91024F00021, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91024F00021 an order under another contract?
Yes. 75N91024F00021 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00021 competed?
The extent of competition for 75N91024F00021 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award